Evaluation of Clinical and Radiological Success of Vital Amputation Treatment
1 other identifier
interventional
70
1 country
1
Brief Summary
Total amputation therapy; is a treatment method aimed at maintaining the vitality of the radicular pulp remaining as a result of complete removal of coronal pulp tissue. In cases where pulp is exposed due to caries or trauma, the pulp is vital, bleeding can be controlled during the procedure, no periapical pathology is seen and radicular pulp is healthy. Traditionally, acute pulp pain is thought to be a symptom of irreversible pulpitis, and it is thought that there is little chance of the pulp returning to its normal situation after removal of the irritants. Root canal treatment has been accepted as the gold standard for the treatment of these symptoms. In recent studies, spontaneous or severe pain before procedure has not always indicated that pulp has no repair capacity, and deep carious lesions are not necessarily associated with irreversible pulpal pathology. Histological studies showed that even when caries reach the pulp or degeneration and inflammation were seen in it, there was a healthy section still present in the pulp. Therefore, it is stated that the healthy pulp remaining as a result of total amputation performed by removal of degenerated pulp can be preserved. Furthermore, it is stated that for the healing potential of the remaining pulp tissue, the original signal should be that the bleeding can be controlled after the amputation of the infected pulp tissue. While the most popular method in the treatment of vital pulp is CaOH, the American Academy of Pediatric Dentistry has been reported to be more resistant to dissolution in the protocol in recent years. MTA is a more suitable material because it is more homogeneous, and forms a thicker dentin bridge. However, the MTA requires a long time to harden, it is difficult to manipulate and color. In recent years, researchers have focused on creating new MTA formulations to improve their physicochemical properties without affecting their biocompatibility and bioactivity. NeoMTA Plus is a new fine powder tricalcium silicate. It consists of a water-based gel and powder mixture and the powder-gel mixing ratio may vary depending on the area of use. It is a material similar to MTA Plus. However, in order to avoid tooth discoloration, tantalium oxide used instead of the bismuth oxide and required calcium hydroxide used to induce the formation of mineralized tissue.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2018
CompletedFirst Submitted
Initial submission to the registry
March 18, 2019
CompletedFirst Posted
Study publicly available on registry
March 20, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 15, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2019
CompletedMarch 25, 2019
March 1, 2019
1.1 years
March 18, 2019
March 22, 2019
Conditions
Outcome Measures
Primary Outcomes (3)
Postoperative pain
Using visual analogue scale by participant. It is usually presented as a 100-mm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable". The scale has no other subscales.
12 months
Pulp sensibility
Using cold and electric pulp testings by clinicians
12 months
Radiological evaluation
Standardized periapical radiographs will be taken and monitored
12 months
Study Arms (2)
Control
EXPERIMENTALroot canal treatment will be initiated
NeoMTA Plus
EXPERIMENTALvital pulp treatment using neomta plus will be used.
Interventions
The specimens will be root canal treated conventionally
The specimens will be subjected to vital pulp amputation using NeoMTA Plus.
Eligibility Criteria
You may qualify if:
- Having a lower molar and lower/upper premolars diagnosed with irreversible pulpitis
You may not qualify if:
- Patients with systemic disease
- Negative outcome of pulp sensibility
- Patients presenting abscess
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Elif Kalyoncuoğlu
Samsun, 55139, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ayça T Ulusoy Yamak
ONDOKUZ MAYIS UNIVERSITY, FACULTY OF DENTISTRY DEPARTMENT OF PEDIATRIC DENTISTRY
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assoc.Prof
Study Record Dates
First Submitted
March 18, 2019
First Posted
March 20, 2019
Study Start
November 1, 2018
Primary Completion
December 15, 2019
Study Completion
December 31, 2019
Last Updated
March 25, 2019
Record last verified: 2019-03
Data Sharing
- IPD Sharing
- Will not share